

Supplementary Material

Table S1. Pregnancies with just one invoice of an antihypertensive medication during the pregnancy by ATC group

N (%)	Total	Antiadrenergic agents (C02)	Diuretics (C03)	Beta blocking agents (C07)	Calcium Channel Blockers (C08)	Renin-angiotensin system agents (C09)
Total	529 (100)	59 (11.1)	39 (7.4)	301 (56.9)	30 (5.7)	100 (18.9)
1 st Trimester	194 (36.7)	25 (42.4)	17 (43.6)	81 (26.9)	6 (20)	65 (65)
2 nd Trimester	34 (6.4)	6 (10.2)	2 (5.1)	21 (7.0)	3 (10)	2 (2)
3 rd Trimester	301 (56.9)	28 (47.4)	20 (51.3)	199 (66.1)	21 (70)	33 (33)

Table S2. Main active substance exposure by invoice (total invoices 4,022) during the pregnancy episodes and by trimester. Showing those with frequency >1%

Active Substance	Total Invoices (%)	Invoices Percentage1 st trimester (%)	Invoices 2 nd trimester (%)	Invoices 3 rd trimester (%)
Labetalol	1,022 (25.4)	604 (20.8)	475 (45.1)	658 (39.0)
Enalapril	504 (12.5)	375 (12.9)	41 (3.9)	175 (10.4)
Methyldopa	492 (12.2)	393 (13.5)	301 (28.6)	254 (15.1)
Hydrochlorothiazide	207 (5.2)	160 (5.5)	15 (1.4)	61 (3.6)
Beta blocking agents, selective	200 (5.0)	170 (5.9)	18 (1.7)	41 (2.4)
Amlodipine	183 (4.6)	149 (5.1)	31 (2.9)	50 (3.0)
Nifedipine	143 (3.6)	55 (1.9)	34 (3.2)	83 (4.9)
Hydralazine	109 (2.7)	59 (2.0)	36 (3.4)	59 (3.5)
Atenolol	103 (2.6)	88 (3.0)	7 (0.7)	18 (1.1)
Lisinopril	85 (2.1)	71 (2.4)	5 (0.5)	23 (1.4)
Losartan	78 (1.9)	73 (2.5)	10 (1.0)	12 (0.7)
Bisoprolol	75 (1.9)	64 (2.2)	10 (1.0)	17 (1.0)
Ramipril	69 (1.7)	55 (1.9)	7 (0.7)	19 (1.1)